Sublingual immunotherapy

Allergen immunotherapy (AIT):　AIT is considered the only effective curative therapy for IgE-mediated type I allergic diseases such as allergic rhinitis, asthma, and atopic dermatitis. SLIT (sublingual AIT) has gained popularity in the last decade for the treatment of allergic rhinitis as an alternative to SCIT (subcutaneous AIT) with improved safety and ease of administration. However, SLIT requires a long administration period 3~5 years to induce clinically relevant efficacy and some patients with allergic rhinitis do not respond or show little improvement due to poor adherence and delayed onset of efficacy. Therefore, further improvements in AIT to enhance its efficacy and shorten the treatment duration are strongly desired by the medical community.